anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Age-related declines in olfaction contribute to low quality of life and appear to occur with declines in cognitive function, including diminished episodic memory. We tested the hypothesis that low gray matter volume within cortical regions that support olfaction and episodic memory can explain age-related differences in olfactory and episodic memory functions.
METHODS: T1-weighted images, Sniffin' Sticks olfactory measures, and the NIH Toolbox-Cognition Battery were administered to 131 middle-aged to older adults (50-86 years; 66% female). Correlation was used to examine the associations between these measures. A network-based image processing approach was then used to examine the degree to which spatial patterns of gray matter variance were related to the olfactory and cognitive measures. Structural equation modeling was used to characterize the relative specificity of olfactory, cognitive, gray matter, and aging associations.
RESULTS: Olfactory threshold, discrimination, and identification exhibited small to medium effect size associations with episodic memory performance (rs = 0.27-0.42, ps < 0.002). Gray matter volume within medial temporal and orbitofrontal cortex was also related to olfactory (discrimination and identification) and episodic memory function (rs = 0.21-0.36, ps < 0.019). Age and episodic memory explained the same variance in olfaction that was explained by the medial temporal and orbitofrontal pattern of gray matter volume.
CONCLUSIONS: The results of this cross-sectional study suggest that identifying mechanisms contributing to differences in medial temporal and orbitofrontal cortex will advance our understanding of co-morbid olfactory and cognitive declines.
Exercise increases peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1α) expression, which in turn causes the fibronectin type III domain containing 5 (FNDC5) protein to be produced. This protein is then cleaved, primarily in skeletal muscle fibers, to produce irisin. When the mature FNDC5 is cleaved by proteases, Irisin - which is the fibronectin III domain without the signal sequence - is released. Resistance, aerobic, and high-intensity interval training (HIIT) are recognized as forms of physical exercise that raise irisin levels, and insulin receptor phosphorylation in tyrosine residues, favoring an increase in the activity of the insulin-dependent pathway (PI3K pathway) and assisting in the fight against insulin resistance, inflammation, and cognitive decline. Irisin may represent a promising option for the therapeutic targeting in several brain-related pathological conditions, like Alzheimer's disease (AD), Parkinson's disease (PD), epilepsy, type 2 diabetes, and obesity. Exercise protocols are healthy and inexpensive interventions that can help find cellular and molecular changes in several brain-related pathological conditions. Here, it was reviewed what is known about exercise-produced irisin studies involving AD, PD, epilepsy, type 2 diabetes, and obesity.
The knee joint problems and injuries has been rising as a result of more number of patients getting injuries in various daily livings e.g traffic and industrial accidents Ligamentous injuries are one of the commonest injuries of knee among which occurrence of Anterior cruciate ligament(ACL) injuries are of considerable importance The ACL is actually made up of many bundles of connective tissue and it has course from femur to tibia as shown in picture. The ACL is main ligament which prevents tibia to go outwards and excessive loads. When knee is in straight position ACL has 32mm length and 7-12mm width.ACL has 2 parts anteromedial bundle and posterolateral bundle. During flex position AMB goes into lengthened position and PLB goes into shorten position. It is made up of collagen fibres and its framework has proteins, glycoproteins, elastic systems, and glycoseminoglycans. Because of its elastic property it undergoes into many stresses. And it has nerve supply of tibial nerve and it has arterial supply of middle genicular artery. The Occurrence of ACL injures mostly reported among paediatric and adolescent population as compared to adult population. This factor which raises the contribution of adults to participate in sports are younger age high performance training, awareness of injury and use of better modalities. Short term complications of ACL that include loss of function, pain and reconstructive surgery period of about 24 to 36 weeks required for return to function. Reconstructive surgeries include autogenous or allogeneic graft reconstruction Many studies showed that after reconstructive surgery patients return to sports. Most (82%) patients are able to return to sport activity according to a meta-analysis results; however preinjury levels of performance are attained in only 43-65.7% of cases. Long-term complication of ACL injuries that significantly include osteoarthritis that develop later in life. One of the studies show that 50% of diagnosed patients of meniscus or ACL tear might develop osteoarthritis (OA) in the affected knee in about 10-20 years after surgery and the prevalence and severity of OA has not been shown to reduce by reconstructive surgery. Newer surgical approaches and techniques seems to reduce risk of developing osteoarthritis later in life but still questionable.
AIMS: Physiological cardiac hypertrophy occurs in response to exercise and can protect against pathological stress. In contrast, pathological hypertrophy occurs in disease and often precedes heart failure. The cardiac pathways activated in physiological and pathological hypertrophy are largely distinct. Our prior work demonstrated that miR-222 increases in exercised hearts and is required for exercise-induced cardiac hypertrophy and cardiomyogenesis. Here, we sought to define the role of miR-222 in pathological hypertrophy.
METHODS AND RESULTS: We found that miR-222 also increased in pathological hypertrophy induced by pressure overload. To assess its functional significance in this setting, we generated a miR-222 gain-of-function model through cardiac-specific constitutive transgenic miR-222 expression (TgC-miR-222) and used locked nucleic acid anti-miR specific for miR-222 to inhibit its effects. Both gain- and loss-of-function models manifested normal cardiac structure and function at baseline. However, after transverse aortic constriction (TAC), miR-222 inhibition accelerated the development of pathological hypertrophy, cardiac dysfunction, and heart failure. Conversely, miR-222-overexpressing mice had less pathological hypertrophy after TAC, as well as better cardiac function and survival. We identified p53-up-regulated modulator of apoptosis, a pro-apoptotic Bcl-2 family member, and the transcription factors, Hmbox1 and nuclear factor of activated T-cells 3, as direct miR-222 targets contributing to its roles in this context.
CONCLUSION: While miR-222 is necessary for physiological cardiac growth, it inhibits cardiac growth in response to pressure overload and reduces adverse remodelling and cardiac dysfunction. These findings support the model that physiological and pathological hypertrophy are fundamentally different. Further, they suggest that miR-222 may hold promise as a therapeutic target in pathological cardiac hypertrophy and heart failure.
A total of N=80 participants will be randomized into an EMA-only control group, parallel to the micro-randomized trial intervention group. This group will conduct 14-day EMA only training phase just like the micro-randomized trial group, but will not be switched over to the intervention phase after these initial 14 days. Instead, participants will continue the EMA-only data collection procedure for an additional 30-days (analogous to the 30-day intervention phase of the micro-randomized trial). During these 30 days, the EMA-only control group will continue to receive 3 randomly prompted EMA surveys per day and an additional 3 EMA surveys triggered by smoking reports.
BACKGROUND: Knowing levels and determinants of partnership acquisition will help inform interventions that try to reduce transmission of sexually transmitted infections (STIs) including HIV.
METHODS: We used population-based, cross-sectional data from 47 Demographic and Health Surveys to calculate rates of partner acquisition among men and women (15-49years), and identified socio-demographic correlates for partner acquisition. Partner acquisition rates were estimated as the total number of acquisitions divided by the person-time in the period covered by the survey. For each survey and by sex, we estimated age-specific partner acquisition rates and used age-adjusted piecewise exponential survival models to explore whether there was any association between wealth, HIV status and partner status with partner acquisition rates.
RESULTS: Across countries, the median partner acquisition rates were 30/100 person-years for men (interquartile range 21-45) and 13/100 person-years for women (interquartile range 6-18). There were substantial variations in partner acquisition rates by age. Associations between wealth and partner acquisition rates varied across countries. People with a cohabiting partner were less likely to acquire a new one, and this effect was stronger for women than men and varied substantially between countries. Women living with HIV had higher partner acquisition rates than HIV-negative women but this association was less apparent for men. At a population level, partner acquisition rates were correlated with HIV incidence.
CONCLUSIONS: Partner acquisition rates are variable and are associated with important correlates of STIs and thus could be used to identify groups at high risk of STIs.
Reducing the toxicity of aluminium ions in humans comprises chelating them to form an electron-rich oxine structure. The uncomplexed precursor of the complex is broken down by oxidn., hydrolysis or a coupling reaction in the body, to form substances excreted by the kidney. The complexing agent is pref. an electron-donator-substituted quinoline or quinaldine oxidised at position 8, esp. the 8-hydroxy deriv. masked by an ester or urethane gp. The detoxifying process pref. uses citrate, cis aconitate and/or fluoride together with the complexing agent. USE/ADVANTAGE - Al(3+) ions are suspected of causing Alzheimer's disease, esp. where a deficiency of citrate ions exists. The complexes remove Al(3+) from the brain and bloodstream, and are readily eliminated by the kidneys. They have higher affinity for aluminium than citrate, and can therefore remove aluminium from citrate complexes.
This invention relates to an oil-in-water-in-oil (O/W/O) type multiple emulsion which contains an inner oil phase, a water phase, and an outer oil phase. The inner oil phase is first dispersed in water to form an oil-in-water (O/W) emulsion. Then, the O/W emulsion is further dispersed in the outer oil phase to form the O/W/O type multiple emulsion. The outer oil phase contains an organophilic clay mineral, which can effectively prevent the inter-mixing of the inner oil phase with the outer oil phase, thus, producing an O/W/O type multiple emulsion with excellent storage stability. Upon the using of an oil-soluble compound in the inner oil phase, this multiple emulsion system can prevent the oil-soluble compound from being oxidized. In addition, since different kinds of oils can be selected for the making of the inner and outer oil phases, respectively, the O/W/O type multiple emulsion system allows one to present two different kinds of oils, which have different properties independent from each other, in one emulsion system.
Patients presenting with ST-segment elevation myocardial infarction within 3 hours of symptom onset and satisfying all of the inclusion criteria after informed consent would be randomly allocated to either intravenous N-Acetylcysteine or standard treatment using a 1:1 allocation ratio. Those randomized to IV N-Acetylcysteine would be administered a bolus of 1200 mg over 0.5 hours (in 5% Dextrose) followed by 600mg/hour for the remaining 47.5 hours (in 5% dextrose). A total N-acetylcysteine dose of 29.7 grams is administered over 48 hours. The infusion is continued during the primary percutaneous coronary intervention. Patients would be followed up for a minimum of 90 days. The primary clinical endpoint will be myocardial infarct size measured by late gadolinium enhancement CMR imaging at 3-5 days from first medical contact. Primary feasibility outcome will be the rate of recruitment, the number of patients undergoing cardiac MRI within the stipulated time frame, and completeness of the study data collection.
The Personal Information Form, the Traumatic Childbirth Perception Scale (TCPS), and the short-form Childbirth Self-Efficacy Inventory (CBSEI-32) were utilized for the collection of research data. First of all, the TCPS was applied to the pregnant women, and the pregnant women who obtained a score above 53 points (moderate-level traumatic childbirth perception) from the TCPS were invited to the research. Next, the Personal Information Form and the CBSEI-32 were applied to the pregnant women who agreed to participate in the research. The motivational interviews were held with the pregnant women in the experimental group once a week for four weeks. No initiative was applied to the pregnant women in the control group. The TCPS and CBSEI-32 were applied to all participant pregnant women after four weeks following the first application. The application of the measurement tools took 10-15 minutes.
FIELD: information technologies. ^ SUBSTANCE: method of data storage for storage of a subunit from a data unit. The data unit is distributed along multiple devices in a certain quantity of data subunits. Multiple devices comprise at least two devices, and the method comprises the following stages: collection of a data subunit, using a device that stores a data subunit on a device; and saving metadata that identify data contained in the data subunit. ^ EFFECT: monitoring by means of distribution and saving of data in multiple memory devices of multiple remote monitoring devices. ^ 8 cl, 5 dwg
D-21 Begin Pembrolizumab 200mg. D-7 begin Metformin ER 1000mg daily. D1 begin Metformin ER 2000mg daily. Continue Pembrolizumab 200mg every 3 weeks.
INTRODUCTION: Despite the mortality benefits of alcohol cessation and alcohol treatment, few patients with alcohol-related liver disease (ALD) get such treatment. To understand reasons for low treatment rates, we performed a qualitative mental models study to explore how ALD patients understand factors influencing alcohol cessation, relapse and their liver health.
METHODS: Using a mental models framework, we interviewed experts in alcohol use disorder (AUD) and ALD to determine factors influencing alcohol cessation, risk of relapse and liver health. An expert influence diagram was constructed and used to develop a patient interview guide. We recruited participants with ALD enrolled in hepatology or transplant clinics at a single tertiary-care center. We conducted interviews either face-to-face or by phone, per participant preference. We transcribed all interviews verbatim and analyzed them using combined deductive coding schema based on both the interview guide and emergent coding.
RESULTS: 25 (10 women, 15 men) participants with a mean age of 57 years completed interviews. 68 % had decompensated cirrhosis. Major omissions included gender (as a factor in alcohol use or liver disease) and the influence of benzodiazepines/opioids on relapse. Misconceptions were common, in particular the idea that the absence of urges to drink meant participants were safe from relapse. Conceptual differences from the expert model emerged as well. Participants tended to view the self as primary and the only thing that could influence relapse in many cases, resulting in a linear mental model with few nodes influencing alcohol cessation. Participants' risky drinking signals (i.e., elevated liver enzymes) differed from known definitions of hazardous or high-risk drinking, which largely emphasize dose of alcohol consumed irrespective of consequences. Finally, participants sometimes viewed stopping on one's own as the primary means of stopping alcohol use, not recognizing the many other nodes in the influence diagram impacting ability to stop alcohol.
CONCLUSION: Patients with ALD had critical misconceptions, omissions, and conceptual reorganizations in their mental models of the ability to stop alcohol use. Attention to these differences may allow clinicians and researchers to craft more impactful interventions to improve rates of alcohol abstinence and AUD treatment engagement.
Patients receive radium Ra 223 dichloride as in Arm I. Patients with radiographic progression may crossover to Arm I. If patients have already completed all 6 infusions of radium, they will receive monotherapy with olaparib. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.
The present disclosure provides a method for assessing occurrence of heart failure including following steps. A heart failure assessment program is provided. A target electrocardiogram signal data of a subject is provided. A data pre-processing steps is performed, wherein a data processing module is used to pre-process the target electrocardiogram signal data so as to obtain a processed target electrocardiogram data. An analysis step is performed, wherein the processed target electrocardiogram data is analyzed by the heart failure assessment program so as to obtain a heart failure assessment result. Therefore, it can effectively assess whether a subject has heart failure or not and further evaluate the condition of sleep apnea, and has the potential of clinical application.
The invention relates to a material for producing products (1) having fibrinolytic and/or antibacterial properties. Said material has at least one matrix (2), which is compatible with body tissue and in which a molecular sieve is incorporated. Said molecular sieve is loaded with: at least one active substance (Z) having a fibrinolytic or antibacterial effect; or at least one first active substance (Z1) having a fibrinolytic effect and a second active substance (Z2) having an antibacterial effect. The corresponding molecular sieve/active substance adduct (3) releases the active substance(s) in conjunction with the aqueous body fluid when the matrix (2) is in contact with the body tissue (4). The inventive material is characterized in that the molecular sieve/active substance adduct (3) additionally contains water of crystallization to such an extent that the molecular sieve is partially dehydrated with regard to a sufficient basic molar quantity (m) of water of crystallization. The molecular sieve is loaded with the reduced molar quantity (m') of water of crystallization with the active substance(s) (Z, Z1, Z2) so that an adsorption of water with the desorption of the corresponding active substance occurs when the matrix (2) is in contact with the body tissue (4), whereby the water of crystallization of the molecular sieve increases. The invention also relates to an advantageous method for producing the inventive active substance.
Keratinocytes are major cellular components of the skin and are strongly involved in its homeostasis. Oncogenic events, starting mainly from excessive sun exposure, lead to the dysregulation of their proliferation and differentiation programs and promote the initiation and progression of non-melanoma skin cancers (NMSCs). Primary melanomas, which originate from melanocytes, initiate and develop in close interaction with keratinocytes, whose role in melanoma initiation, progression, and immune escape is currently being explored. Recent studies highlighted, in particular, unexpected modes of communication between melanocytic cells and keratinocytes, which may be of interest as sources of new biomarkers in melanomagenesis or potential therapeutic targets. This review aims at reporting the various contributions of keratinocytes in skin basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma, with a greater focus on the latter in order to highlight some recent breakthrough findings. The readers are referred to recent reviews when contextual information is needed.
PCT No. PCT/EP93/00011 Sec. 371 Date Oct. 22, 1993 Sec. 102(e) Date Oct. 22, 1993 PCT Filed Jan. 7, 1993 PCT Pub. No. WO93/16677 PCT Pub. Date Sep. 2, 1993The composition for the oxidative dyeing of hair contains at least one coupler of the general formula    <IMAGE>  (I)  where R is a straight-chain or branched C1- to C4-alkyl group, X is chlorine or fluorine, and R1 is a straight-chain or branched C1- to C4-alkyl group or a straight-chain or branched C2- to C4-hydroxyalkyl group. The 5-halogen-2,4-bis(alkylamino)-1-alkylbenzenes of the formula (I) are novel. The couplers of the general formula (I) may be obtained through simple chemical reactions, are easily soluble in water and have an outstanding shelf stability, in particular as a constituent of the hair dye composition described here. The dyeing results which can be achieved with the hair dye composition according to the invention are particularly distinguished by the color intensity of the red hues, in addition to the multitude of shades, and by a good purity of color with respect to blue hues.
The present invention relates to colorless transparent health care wine for traumatic injuries and a preparation method thereof. The wine comprises the raw materials of the following proportion by weight: 26 to 36% of notoginseng, 18 to 28% of eucommia bark, 18 to 30% of Chinese angelica, 20 to 30% of dipsacus root, 20 to 32% of buck grass, 3 to 8% of saffron, 18 to 28% of sappan wood, 18 to 30% of verbena, 12 to 20% of corydalis tuber, and 20 to 30% of drynaria. The colorless transparent health care wine is manufactured by using the methods of steaming, boiling, dipping, soaking and brewing method to make each medicine herb respectively dissolved in wine according to the different characteristics of various plants (medicine). The wine uses a unique formula and the unique preparation method, and solves the problems of deep color and bitter odor of common medicine wine. The present invention not only has colorless transparent and clear appearance, but also has the good effects of enhancing the immunity of a human body, and treating traumatic injuries. Besides, the present invention not only can satisfy the wine drinking habits of people, but also can ensure that people can not drink too much so as not to harm health, and can not affect normal operation and life after drunkenness for people. Therefore, the present invention is unique effective and ideal health care wine for treating traumatic injuries.
Patients receive ribociclib orally PO QD, palbociclib PO QD on days 1-21, and/or abemaciclib PO BID on days 1-28. Patients also receive letrozole PO QD or anastrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ABSTRACT OF THE DISCLOSURE         A pharmaceutical preparation containing ibuprofen is disclosed.  In the preparation, the ibuprofen particles are enve-loped by a coating of a hydro-colloid and fumaric acid.  Prefer-ably, the hydro-colloid comprises xanthan gum and/or maltodex-trin.  This preparation reduces the tendency of ibuprofen to irritate the esophagus and the gastrointestinal tract when taken orally.  An effervescent mixture of the ibuprofen containing pre-paration can be prepared by incorporating citric acid and calcium carbonate into the mixture.  A process for the manufacture of the ibuprofen containing preparation is also disclosed.  In this pro-cess, ibuprofen particles are coated with the hydro-colloid and fumaric acid under vacuum conditions in a vacuum mixing machine and the resulting preparation is thereafter vacuum-dried.